Liu, Kathy Y;
Ivenso, Chineze;
Howard, Rebecca;
Rapaport, Penny;
Reeves, Suzanne;
Banerjee, Sube;
Schneider, Lon S;
... Agitation MCID Study Group, .; + view all
(2025)
Three approaches to determining clinically meaningful benefit
on the Cohen-Mansfield Agitation Inventory in dementia
clinical trials for agitation.
Alzheimer's & Dementia: Translational Research & Clinical Interventions
, 11
(2)
, Article e70099. 10.1002/trc2.70099.
Preview |
Text
Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield Agitation Inventory in dementia clinica.pdf - Published Version Download (556kB) | Preview |
Abstract
INTRODUCTION: There is a need to understand the clinical meaningfulness of symptom score changes in treatment trials of dementia-related agitation. We estimated minimal clinically important differences (MCIDs) for commonly employed agitation scales and contextualized their clinical application. / METHODS: We employed anchor- and distribution-based approaches to determine changes in scores corresponding to minimal symptom improvement. An opinion-based approach assessed expert clinicians’ agreement on the meaningfulness of score changes through three clinical vignettes. / RESULTS: Minimal symptom improvement for Cohen-Mansfield Agitation Inventory total score ranged from −4 (over <1 month) to −11 (over 1 to 3 months) points. Greater symptom severity correlated with higher MCID estimates. The clinical importance of score changes was influenced by treatment duration, pharmacological side effects, and impacts on caregiver distress/time resources. / DISCUSSION: The clinical meaningfulness of agitation scale MCIDs is influenced by trial-specific and clinical factors. Shorter trial durations and measuring caregiver distress/time resources enhance the clinical interpretation of agitation treatment outcomes. Highlights: *For the CMAI total score, the MCID was −4 points over shorter time scales and −11 points for longer time scales. / / *Worse agitation severity was associated with higher MCID estimates. / / *There was high expert consensus that a noticeable treatment benefit was not worthwhile if it occurred after 12 weeks or had no impact on caregiver/staff distress/time resources.
| Type: | Article |
|---|---|
| Title: | Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield Agitation Inventory in dementia clinical trials for agitation |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/trc2.70099 |
| Publisher version: | https://doi.org/10.1002/trc2.70099 |
| Language: | English |
| Additional information: | © The Author(s), 2025. This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/ |
| Keywords: | agitation, Alzheimer, clinically meaningful benefit, dementia, MCID, trial |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry > Mental Health of Older People |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10212966 |
Archive Staff Only
 |
View Item |
